Kinetic resolution of (*RS*)-1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol: a metoprolol intermediate and its validation through homology model of *Pseudomonas fluorescens* lipase†

Surbhi Soni,[a] Bharat P. Dwivedee,[b] Vishnu K. Sharma[c] and Uttam C. Banerjee (ID) *[b]

In the present study *Pseudomonas fluorescens* lipase (PFL) was screened as a time efficient biocatalyst for the kinetic resolution of a racemic intermediate [(*RS*)-1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol] of metoprolol, an important selective β_1-blocker drug. PFL selectively acylated the *R*-form of this racemic intermediate in a short duration of 3 h. Different reaction parameters were optimized to achieve maximum enantioselectivity. It was found that at 30 °C, enzyme activity of 400 units and substrate concentration of 10 mM gave a high enantioselectivity and conversion in an optimum time of 3 hours (C = 50.5%, ee_p = 97.2%, ee_s = 95.4%, E = 182). To validate these experimental results, the 3D structure of PFL was built using homology modelling. Validation of the model through Ramachandran plot (92.7% in favored region), Errat plot (overall quality factor, 79.27%), Verify-3D score (86.19) and ProSA_*Z* score (−6.24) depicted the overall good quality of the model. Molecular docking of the *R*- and *S*-enantiomers of the intermediate, which was performed on this model, demonstrated a strong H-bond interaction (1.6 Å) between the hydroxyl group of the *R*-enantiomer and Arg54, a key binding residue of the catalytic site of PFL, while no significant interaction with the *S*-enantiomer was observed. Thus, the outcome of this docking study was in agreement with the experimental data, clarifying that PFL preferentially catalysed the transesterification of the *R*-enantiomer into the corresponding ester, leaving the *S*-enantiomer intact.

Introduction

The growing demand of optically pure compounds for applications in pharmaceutical, chemical, agricultural and cosmetic industries is well understood. The increased interest in these compounds can be clearly attributed to the better understanding of chirality and its importance in synthetic reactions.[1,2] As the predominant outlook of the industry is always on economically expedient, dependable and scalable processes with minimal waste generation, biocatalysis has become a cornerstone for the synthesis of chiral intermediates.[3] Biocatalysis involves the application of enzymes in a suitable form (whole-cell, immobilized or commercial preparation) to catalyze chemical reactions.[4,5] Lipases as biocatalysts have earned a distinguished position in the field of chiral synthesis due to

their excellent chemo-, regio- and enantioselectivity.[6] Lipases obtained from different sources belong to the α/β-hydrolase folding group. Specific sequences of the α-helices and β-strands are responsible for the hydrolyzing activity of lipases.[7] Lipases are widely applied in kinetic resolution, where the lipase discriminates between two enantiomers of the racemic mixture and selectively catalyzes a faster conversion of one enantiomer to the product. This is a convenient method for separation of both enantiomers from a racemic mixture.[8] The rationality of lipase catalyzed biocatalysis as a compatible method for enantiopure synthesis is further augmented by the incorporation of computational strategies.[9] Computational chemistry provides an effective set of tools to simulate the biocatalytic reactions *in silico* and help in the assessment of the effectiveness of the process, thereby validating the experimentation.[10] One key computational methodology is the docking of small molecules into the active site of lipase.[11] The utilization of docking studies enables the fast evaluation of enantioselectivity and is of prime interest to suggest a plausible biotransformation reaction. This enables expensive experimentation to be directed and focused, thereby speeding up bioprocess development.[12]

β-Aryloxyalcohols are useful building blocks in the synthesis of several biologically active compounds. Metoprolol, 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol, a selective

[a]*Department of Biotechnology, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, 160062, Punjab, India*

[b]*Department of Pharmaceutical Technology (Biotechnology), National Institute of Pharmaceutical Education and Research, S.A.S. Nagar 160062, Punjab, India. E-mail: ucbanerjee@niper.ac.in*

[c]*Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar 160062, Punjab, India*

β_1-adrenergic blocking agent, is used in the treatment of angina and hypertension. It is well established that the desirable therapeutic activity of metoprolol resides mainly in the (S)-enantiomer.[13] A number of chemical methods have been described in the literature for the synthesis of enantiopure metoprolol.[14–22] However, most of the chemical synthesis methods suffer from some disadvantages, such as poor enantioselectivity, long reaction time, hazardous reaction conditions, formation of by products, and higher cost. Biocatalytic approach has also been used for the synthesis of chiral intermediates of metoprolol.[23]

To the best of our knowledge, herein, we report for the first time the homology model of PFL and its application to validate the R-selectivity of PFL in the kinetic resolution of a racemic intermediate of metoprolol. In the present study, the racemic intermediate [(RS)-1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol] of metoprolol was chemically synthesized. Various commercial lipase preparations were screened for the kinetic resolution of this racemic intermediate. Among them, PFL was selected as the most suitable lipase. The reaction parameters were optimized using 'one-factor at a time' approach. Furthermore, to validate the experimental results, a homology model of PFL was built since it was not available. The developed homology model was utilized for the molecular docking analysis wherein experimental observations were validated by docking the R and S form of intermediate into the active site of PFL.

Results and discussion

Chemical synthesis of racemic intermediate, (RS)-4

β-Aryloxyalcohols are key intermediates in the preparation of metoprolol. The fundamental structure of metoprolol comprises aryloxypropanolamine. The aromatic ring substituents govern the hydrophobicity of the molecule. Branched alkyl amine substituents present in metoprolol are essential for the β-antagonist activity.[24] A convenient protocol for the preparation of β-aryloxyalcohols requires the synthesis of epoxide intermediates with phenols[25–27] and subsequent ring-opening of the epoxides.[28,29] The racemic intermediate (RS)-4 of metoprolol was prepared via a chemical route. Detailed discussion regarding the synthetic schemes has been furnished in the Experimental section.

Screening of suitable biocatalysts using experimental approach

Lipases are interfacial enzymes and display prodigious stereo-, chemo-, and regioselectivity.[30] In the present study, (RS)-4 was subjected to lipase catalyzed kinetic resolution (Scheme 1). Five commercially available lipases [Thermomyces lanuginosus (TLL), Candida rugosa (CRL), Pseudomonas fluorescens (PFL), Candida antarctica lipase A (CALA) and Candida antarctica lipase B (CALB)] were screened for the kinetic resolution of (RS)-4 using vinyl acetate as an acyl donor and toluene as a solvent. Interestingly, Pseudomonas fluorescens lipase (PFL) was found to be the most suitable biocatalyst (Table 1). PFL resolved (RS)-4 to the corresponding (R)-ester and (S)-alcohol products, displaying

Scheme 1 Kinetic resolution of (RS)-4 using various lipases.

good enantioselectivity and conversion. Moreover, PFL catalyzed the kinetic resolution of the racemate in a short time. This behaviour of PFL towards the rapid enantioselective conversion may be due to the favourable interactions between the amino acid residues in the active site and the ligands.

Optimization of reaction parameters for kinetic resolution

To achieve a successful and efficient lipase catalyzed reaction, conditions favouring rapid progress and irreversibility must be taken into account. Various reaction parameters such as type of solvents, reaction time and temperature, type of acyl donors, substrate and enzyme concentrations etc. were optimized. The substrate concentration (10 mM), enzyme concentration (400 IU), solvent (toluene), acyl donor (vinyl acetate), temperature (30 °C), and reaction time (3 h) were optimized on the basis of high enantiomeric excess (ee$_s$ & ee$_p$), high conversion rate (>49%) and enantiomeric ratio ($E \leq 200$) [detailed discussion on each parameter is given in the next section]. Under these optimized conditions, PFL performed the acylation of (R)-enantiomer of (RS)-4 with a final result of $C = 50.5\%$, ee$_p = 97.2\%$, ee$_s = 95.4\%$, $E = 182$.

Effect of solvents

Several examples of improved regioselectivity and enantioselectivity of lipases in organic reactions have been observed. Lipases show good stability in organic solvents.[31] One of the important reasons for such a behaviour is that hydrophilic solvents have a higher tendency to strip the tightly bound water, which is necessary for the catalytic activity of lipase. Organic solvents have a lesser tendency for this, making them a better reaction medium for lipase catalyzed reactions.[32] Considering these facts, different organic solvents with a diverse range of log P values were examined for the kinetic resolution of (RS)-4 with vinyl acetate using PFL. The best result was obtained using toluene with the highest percentage conversion (50.5%), enantiomeric excess (97.4% ee$_s$ & 95.5% ee$_p$) and E-value 188 (Fig. 1A).

Effect of acyl donors

Enantioselectivity in the lipase mediated reactions originates during the deacylation step with the nucleophilic attack of the alcohol leading to the formation of the first acyl–enzyme complex.[33] Hence, the type of acyl donor also has a pivotal role in the progress of the reaction. Among the different acyl donors [BA = benzyl acetate, EA = ethyl acetate, IPA = isopropenyl acetate, VA = vinyl acetate], vinyl acetate showed the best results in the kinetic resolution of (RS)-4. Vinyl acetate is an enol ester

Table 1 Screening of lipases for the transesterification of (RS)-**4** with vinyl acetate[a]

S. no.	Lipase	% C^b	ee_s^c	ee_p^d	E^e
1	*Thermomyces lanuginosus* (TLL)	50.0 ± 1.21	74.4 ± 2.95	74.3 ± 2.31	14.9 ± 3.51
2	*Candida antarctica* immobilized (CAL B)	50.3 ± 2.98	70.8 ± 3.23	69.9 ± 1.99	11.7 ± 3.78
3	*Candida antarctica* immobilized (CAL-A)	51.2 ± 1.27	93.7 ± 3.01	89.5 ± 2.08	62.9 ± 1.76
4	**Pseudomonas fluorescens (PFL)**	**50.0 ± 1.58**	**96.2 ± 2.69**	**96.1 ± 3.26**	**200 ± 2.65**
5	*Candida rugosa* (CRL)	53.5 ± 2.25	95.2 ± 2.84	82.8 ± 2.76	39.3 ± 1.82

[a] Conditions: (RS)-**4** (20 mM) in toluene (1 mL) was treated with vinyl acetate (5.4 mmol) at 30 °C in the presence of different lipases (300 IU mL^{-1}). [b] % conversion were calculated from the enantiomeric excess (ee) of (S)-**4** and (R)-**5** as follows: conversion (C) = $ee_s/(ee_s + ee_p)$. [c] Enantiomeric excess of (S)-**4** was determined by HPLC analysis (Daicel Chiralcel OD-H column) 90 : 10; hexane : IPA, flow rate of 1.0 mL min^{-1}, detected at 254 nm. [d] Enantiomeric excess of (R)-**5** was determined by HPLC analysis (Daicel Chiralcel OD-H column) 90 : 10; hexane : IPA, flow rate of 1.0 mL min^{-1}, detected at 254 nm. [e] E value were calculated using the formula: $E = \ln[ee_p(1 - ee_s)/(ee_p + ee_s)]/\ln[ee_p(1 + ee_s)/(ee_p + ee_s)]$.[35]


Fig. 1 Effect of (A) solvents [Tol = toluene, Hex = *n*-hexane, Hep = *n*-heptane, DEE = diethyl ether, But = *n*-butanol, Iso = isooctane]; (B) reaction time on PFL catalyzed kinetic resolution of [(RS)-**4**].

that forms unstable enol as a by-product and rapidly tautomerizes to form the corresponding aldehydes or ketones making the reaction completely irreversible.[34] The highest percentage conversion (50.1%), enantiomeric excess (96.4% ee_s & 96.1% ee_p) and E-value (205) of PFL catalysed kinetic resolution of (RS)-**4** in toluene were obtained with vinyl acetate as the acyl donor (Fig. 2D).

Effect of reaction time

The most interesting part of the study is the short duration in which PFL catalyzes the enantioselective reaction of (RS)-**4**. In the reaction of (RS)-**4**, PFL took 3 h for 50.0% conversion with 95.5% ee_s, 96.0% ee_p, and E-value of 183.5 (Fig. 1B). PFL started to display good enantioselectivity and conversion rate very early in the reaction, in only over 30 min to deliver the best result. Although the values of enantioselective ratio and percentage conversion along with enantiomeric excess were low at the early onset of the reaction, PFL exhibited the best results promptly. Such high reactivity of PFL towards the intermediate is justified with the interaction of the (R)-enantiomer at the active site of the enzyme, as later validated by the docking study. During the course of the reaction, the enantioselectivity gradually decreased and PFL exhibited non-selective behaviour. In a recent study on kinetic resolution of racemic atenolol, PFL has been reported to give (S)-enantiomer in 24 h.[36] In another study, PFL catalyzed the kinetic resolution of some novel antifungal N-substituted benzimidazole derivatives in more than 72 h.[37] Thus, the rapid action of PFL on (RS)-**4** with high degree of enantioselectivity and rate of conversion reported here is suggestive of strong interaction between (RS)-**4** and PFL, thereby revealing a better chemoenzymatic process that could be used for the synthesis of enantiopure metoprolol in a shorter time.

Fig. 2 Effect of (A) enzyme concentration; (B) substrate concentration; (C) temperature; and (D) acyl donors [BA = benzyl acetate, EA = ethyl acetate, IPA = isopropenyl acetate, VA = vinyl acetate] on PFL catalyzed kinetic resolution of [(RS)-4].

Effect of substrate concentration

The effect of substrate concentration on the enantioselectivity and conversion of an enzymatic reaction has been extensively studied in the literature.[38] Thus, we performed the reaction using a range of substrate concentration from 1 to 30 mM. The optimal substrate concentration was 10 mM, at which PFL displayed good conversion rate of 49.2% along with the ee_s, ee_p and E-value of 93.4%, 96.3% and 187, respectively (Fig. 2B).

Effect of enzyme concentration

A biocatalytic transformation occurs at the active sites of the enzyme. Owing to the kinetic consideration of the enzymes, an optimal enzyme concentration, where all the active sites are acquired by substrate molecules, should be identified. This has a direct effect on the cost effectiveness of the process.[39] Thus, we optimized the enzyme concentration to obtain the highest enantioselectivity. The reaction of (RS)-4 was carried out using different concentrations (100, 200, 300, 400, 600 IU) of PFL in toluene. At the concentration of 400 IU, PFL showed the highest conversion 50.6% and ee_s, ee_p and E-value were found to be 97.4%, 95.1% and 173, respectively (Fig. 2A). Further increase in enzyme concentration reduced the enantioselectivity of the reaction, probably due to the non-selective interaction of the enzymes with the substrates at higher enzyme concentration.

Effect of temperature

The effect of temperature on the degree of enantioselectivity and percentage conversion was investigated by performing the reactions at a range of temperatures (4, 20, 25, 30, 40, 50 and 60 °C). In the reactions of (RS)-4, PFL catalyzed the conversion with the highest enantioselectivity at 30 °C. The increase in temperature showed a gradual demise in the enantioselective resolution of the (R) and (S) forms of the racemic alcohol. For

(RS)-4, the conversion at 30 °C was 49.3%, with 93.8% ee_s, 96.5% ee_p and 201 E-value after 3 h of reaction (Fig. 2C).

Validation of suitable biocatalyst using computational approach

The structural information of several lipases is well exploited to give an insight into the catalytic mechanism and enantiopreference of the biocatalytic reaction.[40] During the experimental study, PFL exhibited biocatalytic reaction in only three hours. This outcome encouraged us to explore the interaction between PFL and the substrate. Homology modeling and docking studies of two enantiomers into the active site of PFL were carried out to substantiate the experimental outcomes of this study (Table 2).

Development of homology model for *Pseudomonas fluorescens* lipase. Since the 3D crystal structure information of PFL was not available in the Protein Data Bank (PDB) [http://www.rcsb.org], we focused on the development of its homology model. The protein sequence of (PFL) was retrieved from UniProt Knowledge Base webserver[41] [primary accession no. P26504 (LIPA_PSEFL)] with a total length of 449 amino acids. This sequence was utilized as a target or a query to find out the suitable template sequence and crystal structure within the Protein Data Bank using PSI-BLAST online program. The PSI-BLAST search program revealed *Pseudomonas* sp. MIS38 (PDB code 2Z8X) as the best template for PFL. The template PDB (2Z8X) was selected on the basis of query cover (93%), percent identity (63%) and resolution of the template PDB crystal structure (1.48 Å). Alignment of the target and template sequence was carried out using Modeller 9.5v. A total of 50 models were generated using model building script of Modeller 9.5v. The best model was selected on the basis of DOPE score and the alignment of the built model with the template PDB.

Table 2 Optimum reaction conditions for PFL catalysed kinetic resolution of (RS)-4[a]

Physicochemical parameter	Optimum parameter	C (%)[a]	ee_s (%)[b]	ee_p (%)[c]	E[d]
Solvent	Toluene	50.5 ± 2.80	97.4 ± 2.50	95.5 ± 2.33	188 ± 3.79
Acyl donor	Vinyl acetate	50.1 ± 2.21	96.4 ± 2.17	96.1 ± 2.35	205 ± 2.65
Reaction time	3 h	49.9 ± 2.00	95.5 ± 2.17	96.0 ± 3.07	184 ± 3.51
Temperature	30 °C	49.3 ± 2.34	93.8 ± 2.16	96.5 ± 2.03	201 ± 4.04
Substrate conc.	10 mM	49.2 ± 3.00	93.4 ± 2.06	96.3 ± 1.91	187 ± 3.61
Enzyme conc.	400 IU (20 mg mL^{-1})	50.6 ± 2.54	97.4 ± 2.40	95.1 ± 2.27	173 ± 3.06

[a] a, b, c, d are the reaction conditions and equations described in Table 1.

Ramachandran plot was generated for the selected model, and the residues constituting the part of outlier region were refined using loop-refinement script of Modeller 9.5v.

To validate the quality of the developed PFL homology model, various online validation tools like ERRAT plot, Ramachandran plot, ProSA, ProQ and Verify-3D *etc.* were utilized. In the Ramachandran contour plot[42] of PFL (Fig. 3A) 92.4% residues were in favored regions, 5.6% in additionally allowed regions and 2.0% residues in outlier regions. The modeled structures were also validated by ERRAT plot,[43] which showed an overall quality factor of 79.27 as illustrated in Fig. 3C. This was close to the overall quality factor of the template protein (81.85). Verify-3D program was used to validate the stereochemical quality of the model.[44] The residues with a scoring function over 0.2 are considered to be reliable. Furthermore, 86.2% of the residues had a score over 0.2. This validated the good quality of the predicted model[45] as shown in Fig. 3D. Furthermore the structure was analyzed using the ProSA Z-score to assess the quality of the model. The ProSA Z-score value for PFL was −6.24, which falls within the range for native set of proteins having the same size (Fig. 3B). If the Z-score of a model structure is located outside the range characteristic for native proteins from different sources (X-ray and NMR), it indicates an erroneous structure.[46] Thus ProSA Z-score indicated a good correlation between the modeled PFL and the native structure (PDB-2Z8X) in almost of the parts of the sequence. The ProQ LG score, which also predicts the quality of a model protein, was 3.73. It indicated that the developed model is of good quality


Fig. 3 Validation of homology model of PFL: (A) Ramachandran plot (B) ProSA Z-score (C) Errat plot (D) Verify-3D plot.

Table 3 Comparison of the model validation parameters for target and template proteins

Validation parameters	2Z8X	PFL
Ramachandran plot		
Favoured	98.4%	92.4%
Allowed	1.5%	5.6%
Outliers	0.2%	2.0%
Errat plot (overall quality factor)	81.85	79.27
Verify-3D	98.54	86.19
ProSA_Z score	−10.66	−6.24
ProQ server_LG score	5.85	3.73

(LG score > 3). Comparative analysis of template protein (PDB code 2Z8X) and target protein (PFL) is given in Table 3. Finally, energy minimization of the homology model of PFL was performed using Prime module of Schrodinger. The overall results from these model validation tools revealed good quality of the model for PFL.

Molecular docking of *R* and *S* enantiomers of (*RS*)-4 in the active site of *Pseudomonas fluorescens* lipase. The information regarding the active site of PFL was obtained from literature. The X-ray crystal structure of lipases shows the catalytic triad composed of Ser–His–Asp/Glu residues and an oxanion hole containing the –NH groups of the peptide backbone.[47] Ser206, Asp254 and His312 constituted the catalytic triad of PFL, which was identical to the catalytic triad (Ser207, Asp255, and His313) of *Pseudomonas* sp. MIS38 lipase.[48] Tyr29, Gly53, and Arg54 are the parts of the oxanion hole in PFL. According to the well-known 'ping-pong bi-bi' mechanism of enantioselective transesterification by lipases,[49] the hydroxyl group of Ser residue acts as a nucleophile, and the imidazole moiety of His residue acts as a base. The acyl–enzyme intermediate (a tetrahedral intermediate) is stabilized through hydrogen bonds and electrostatic

interactions between the carbonyl O atom of the acyl group and the –NH groups present in the oxanion hole.

It is followed by the nucleophilic attack by an alcohol, leading to the formation of an ester.[50] The acyl–enzyme intermediate was prepared by the acylation of the hydroxyl group of Ser206. Molecular docking of *R* and *S* enantiomers of (*RS*)-4 was performed into the acylated enzyme active site, using Schrodinger's Glide module.[51] It has been well established that the *R* and *S* enantiomers of the substrate interact differently with the residues at the active site of the lipase.[26] Stereochemical rules have been proposed for the determination of enantioselectivity. A large number of studies have established an empirical rule that states the *R*-preference of the stereochemical trend observed for lipase catalyzed kinetic resolution of secondary alcohols.[52] The *R*-enantiomer (*R*)-4 showed strong interaction with Arg54 residue, which forms a part of the oxanion hole of PFL, with a H-bond distance of 1.6 Å (Fig. 4A), while the *S* enantiomer (*S*)-4 showed no significant interactions needed for the lipase catalyzed reaction (Fig. 4B). The *G* score for the *R*-enantiomer was −5.33, while the *S*-enantiomers had a lower score of −4.50. This outcome of the docking study is in agreement with experimental data, clarifying that PFL preferentially catalyzed the transesterification of the *R*-alcohol. However, this selectivity was time dependent. Initially, PFL catalyzed the reaction very fast in favor of transesterification of the *R*-enantiomer. The maximum conversion of (*RS*)-4 into the corresponding ester (*R*)-5 was achieved in 3 h. The result obtained in 3 h was $C = 50.0\%$, $ee_s = 95.5\%$, $ee_p = 96.0\%$, and $E = 183.5$.

Conclusions

The methodology of complementing a biocatalytic reaction with *in silico* studies, which is corroborated by this work, is a time-efficient and reliable process. The present study involves screening of various lipases and selecting *Pseudomonas*


Fig. 4 Interaction of ligands (A) [(*R*)-4] and (B) [(*S*)-4] with *Pseudomonas fluorescens* lipase (PFL).

fluorescens lipase as an expeditious biocatalyst, performing the kinetic resolution of the racemic intermediate of metoprolol in a short duration of three hours. The biocatalytic reaction yields the (S)-alcohol, which can be directly utilized in the synthesis of (S)-metoprolol. A suitable homology model for PFL was successfully developed, validated and used for docking to analyse the difference in interaction of two enantiomers with PFL. The *R*-enantiomer presented a higher docking score and stronger H-bond interaction than the *S*-enantiomer. Both approaches proved to be advantageous to select a suitable lipase for the kinetic resolution. Under the optimized conditions, PFL exhibited selective acylation of the (R)-enantiomer of (RS)-**4** [$C = 50.5\%$, $ee_p = 97.2\%$, $ee_s = 95.4\%$, $E = 182$]. The study presents a versatile biocatalyst giving speedy and good result for the enantiopure synthesis of the metoprolol intermediate. This simple, cost effective and green approach may likewise be explored for the synthesis of various enantiopure drugs using *Pseudomonas fluorescens* lipase as a biocatalyst.

Experimental

Materials

4-(2-Methoxyethyl)phenol, (RS)-epichlorohydrin, and (R)-epichlorohydrin were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). Anhydrous Na_2SO_4 and K_2CO_3 were obtained from Merck (Germany). HPLC grade solvents were obtained from Merck (Germany). *Candida antarctica* immobilized (CALA and CALB), *Candida rugosa* lipase, *Thermomyces lanuginosus* lipase and *Pseudomonas fluorescens* lipase were purchased from SIGMA (St. Louis, Missouri, USA). TLC plates were purchased from Merck (Germany). Silica gel (60–120 mesh) for column chromatography was obtained from SRL (India).

Synthesis of 1-chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol (RS)-4

4-(2-Methoxyethyl)phenol (**1**) (10 mM, 1 eq.) and K_2CO_3 (10 mM, 2 eq.) were mixed and refluxed at 85 °C in acetonitrile. After 30 min, (RS)-epichlorohydrin [(RS)-**2**] (10 mM, 1.5 eq.) was added dropwise into the reaction mixture. Reaction progression was constantly monitored through TLC. The reaction was completed in 24 h. Recovered product (RS)-**3** was acetylated using acetyl chloride (6.48 mM, 1.5 eq.) in dichloromethane : water (1 : 1) mixture. The reaction was completed in 12 h. Recovered product (RS)-**4** was analyzed by NMR spectroscopy (Scheme 2). Using the same method, the compound **1** was treated with (R)-**2** to afford the epoxide intermediate (S)-**3**. Upon ring opening, using acetyl chloride, (S)-**3** afforded (S)-**4**.

(RS)-2-((4-(2-Methoxyethyl)phenoxy)methyl)oxirane (RS-**3**), ^{1}H NMR (400 MHz; MeOD; Me$_4$Si): δ (ppm): 2.87 (2H, dd), 2.95 (1H, dd), 3.37 (3H, s), 3.6 (2H, t) 4.38 (2H, d), 6.91 (2H, ddd), 7.28 (2H, ddd). ^{13}C NMR (100 MHz, CDCl$_3$): δ (ppm): 35.30, 43.40, 50.10, 58.68, 68.78, 68.86, 114.18, 114.80, 129.58, 130.10, 131.60, 156.99.

(RS)-1-Chloro-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol (RS-**4**), ^{1}H NMR (400 MHz; MeOD; Me$_4$Si) δ (ppm): 2.87–2.83 (2H,

dd), 3.37 (3H, s), 3.68–3.57 (2H, d), 3.79–3.70 (2H, d), 4.08 (2H, d), 4.2 (1H, tt), 6.80 (2H, ddd), 7.11 (2H, dd). ^{13}C NMR (100 MHz, CDCl$_3$): δ (ppm): 35.21, 46.02, 58.65, 69.67, 69.85, 73.81, 114.67, 114.86, 129.62, 130.15, 156.80.

Analysis

All biocatalytic reactions were incubated in an incubator shaker (Kuhner, Switzerland) at 200 rpm. The products from these chemical reactions were analyzed using ^{1}H and ^{13}C NMR with Bruker DPX 400 (^{1}H 400 MHz and ^{13}C 100 MHz) in MeOD and CDCl$_3$, respectively. Chemical shift values were expressed in δ (ppm) units relative to the tetra methyl silane (TMS) as an internal standard. The chiral intermediates were analyzed by HPLC (Shimadzu, Japan) using a Chiralcel OD-H column (4.6 mm × 250 mm, Daicel Chemical, Japan). Mobile phase consisted of hexane : 2-propanol at 90 : 10 (v/v) with a flow rate of 1.0 mL min^{-1}. At 254 nm, the substrate and product were detected. At the abovementioned condition, the retention times of (R)-**4** and (S)-**4** were 12.2 and 13.3 min, respectively. All samples were run under the same conditions as stated previously.

Enantioselectivity was expressed as E value and calculated by eqn (1), substrate enantiomeric excess (ee_s) was calculated by eqn (2), and substrate conversion (C) by eqn (3).

$$E = [\ln(1 - C(1 + ee_p))]/[\ln(1 - C(1 - ee_p))] \tag{1}$$

$$ee_s = (S - R)/(S + R) \tag{2}$$

$$C = ee_s/(ee_s + ee_p) \tag{3}$$

where ee_s and ee_p represent the enantiomeric excess of the substrate and the product, respectively, and (S) and (R) are the enantiomers of racemic substrate (RS)-**4**.[35]

General procedure for the enantioselective transesterification of (RS)-4

(RS)-**4** (20 mmol, 1 eq.) was subjected to transesterification with vinyl acetate (acyl donor) (100 μL) in toluene (900 μL) using commercial lipase preparations. All lipase preparations were individually added; flasks were tightly capped and placed in the shaker at 30 °C and 200 rpm. After completion, the reaction

Scheme 2   Synthesis of (RS)-**4**.

mixture was extracted with toluene and centrifuged, and the supernatant was evaporated under vacuum. Samples for HPLC analyses were filtered and added to 2-propanol, and the enantiomeric excess and ratio were determined.

Optimization of process parameters for kinetic resolution

The influence of various physicochemical parameters on the percentage conversion and enantioselectivity of the lipase catalyzed reaction was investigated. The effect of various organic solvents on the conversion and enantiomeric excess of lipase catalyzed resolution of (RS)-4 was investigated. Kinetic resolution investigation was carried out in 1 mL of the organic solvent at the optimum values of all other reaction parameters. The effect of reaction time on enantioselectivity and percentage conversion was studied by collecting samples at different time intervals till maximum conversion was achieved. The optimization of the acyl donor was performed using various acyl donors (benzyl acetate, ethyl acetate, isopropenyl acetate, and vinyl acetate) for the kinetic resolution of (RS)-4. While studying the effect of acyl donors, all other reaction parameters were kept at their optimum values. The percentage conversion and enantiomeric excess of the product and residual substrate were determined by chiral HPLC. The optimum substrate concentrations for the resolution of (RS)-4 through lipase catalyzed transesterification, using vinyl acetate/hexane and vinyl acetate/toluene, respectively, were determined at different concentrations of substrate (1 to 30 mM). The effect of enzyme concentration on the resolution of (RS)-4 was investigated using different concentrations of lipases (100 to 600 IU mL^{-1}) for the reaction. Conversion and enantiomeric excess of the product and the residual substrate were determined by chiral HPLC. The determination of the optimum temperature for the transesterification of (RS)-4 was carried out at different temperatures from 4 °C to 60 °C. Samples were collected from the reaction mixture at regular time intervals and conversion and enantiomeric excess was determined using chiral HPLC. All other reaction parameters were kept at their optimum values as obtained in earlier experiments.

Methodology for molecular docking

Glide module of Schrödinger software incorporated with the maestro graphical user interface (GUI) was utilized for the molecular docking study. PFL structure was prepared using protein preparation wizard incorporating OPLS_2005 force field. The grid for PFL was generated using the key binding residues mentioned in the literature. Moreover, (R)-4 and (S)-4 ligand structures were drawn using ChemDraw tools and saved in MOL format. These MOL files were opened and prepared using LigPrep module of Schrödinger software and the possible ionization states were generated at neutral pH (7.0 ± 0.5). Finally, prepared ligands were docked in the active site of the lipase using the standard precision (SP) protocol from the glide module of Schrodinger software and 20 poses per ligand were generated. Finally, the best docked conformations (poses) were selected on the basis of G score.

References

1 B. M. Nestl, B. A. Nebel and B. Hauer, *Curr. Opin. Chem. Biol.*, 2011, **15**, 187–193.
2 D. Muñoz Solano, P. Hoyos, M. J. Hernáiz, A. R. Alcántara and J. M. Sánchez-Montero, *Bioresour. Technol.*, 2012, **115**, 196–207.
3 A. Schmid, J. S. Dordick, B. Hauer, A. Kiener, M. Wubbolts and B. Witholt, *Nature*, 2001, **409**, 258–268.
4 S. Sayin, E. Akoz and M. Yilmaz, *Org. Biomol. Chem.*, 2014, **12**, 6634–6642.
5 C. M. Kisukuri and L. H. Andrade, *Org. Biomol. Chem.*, 2015, **13**, 10086–10107.
6 B. P. Dwivedee, J. Bhaumik, S. K. Rai, J. K. Laha and C. Banerjee, *Bioresour. Technol.*, 2017, **239**, 464–471.
7 B. Joseph, P. W. Ramteke and G. Thomas, *Biotechnol. Adv.*, 2008, **26**, 457–470.
8 A. Kamal, M. A. Azhar, T. Krishnaji, M. S. Malik and S. Azeeza, *Coord. Chem. Rev.*, 2008, **252**, 569–592.
9 T. Ema, Y. Nakano, D. Yoshida, S. Kamata and T. Sakai, *Org. Biomol. Chem.*, 2012, **10**, 6299.
10 A. Tafi, A. Van Almsick, F. Corelli, M. Crusco, K. E. Laumen, M. P. Schneider and M. Botta, *J. Org. Chem.*, 2000, **65**, 3659–3665.
11 D. B. Kitchen, H. Decornez, J. R. Furr and J. Bajorath, *Nat. Rev. Drug Discovery*, 2004, **3**, 935–949.
12 G. Sin, J. M. Woodley and K. V. Gernaey, *Biotechnol. Prog.*, 2009, **25**, 1529–1538.
13 J. Agustian, A. H. Kamaruddin and S. Bhatia, *Process Biochem.*, 2010, **45**, 1587–1604.
14 A. V. R. Rao, M. K. Gurjar and S. V. Joshi, *Tetrahedron: Asymmetry*, 1990, **1**, 697–698.
15 M. K. Gurjar, K. Sadalapure, S. Adhikari, B. V. N. B. S. Sarma, A. Talukdar and M. S. Chorghade, *Heterocycles*, 1998, **48**, 1471–1476.
16 S. H. Jung, T. L. Pham, H. K. Lim, H. J. Kim, K. H. Kim and J. S. Kang, *Arch. Pharmacal Res.*, 2000, **23**, 226–229.
17 M. Muthukrishnan, D. R. Garud, R. R. Joshi and R. A. Joshi, *Tetrahedron*, 2007, **63**, 1872–1876.
18 S. Cheng, X. Liu, P. Wang, X. Li, W. He and S. Zhang, *Lett. Org. Chem.*, 2012, **9**, 516–519.
19 H. U. Shetty and W. L. Nelson, *J. Med. Chem.*, 1988, **31**, 55–59.

20 H. Sasai, T. Suzuki, N. Itoh and M. Shibasaki, *Appl. Organomet. Chem.*, 1995, **9**, 421–426.

21 S. Cheng, X. Liu, P. Wang, X. Li, W. He and S. Zhang, *Lett. Org. Chem.*, 2012, **9**, 516–519.

22 T. Roy, S. Barik, M. Kumar, R. I. Kureshy, B. Ganguly, N. H. Khan, S. H. R. Abdi and H. C. Bajaj, *Catal. Sci. Technol.*, 2014, **4**, 3899–3908.

23 A. Kaler, V. S. Meena, M. Singh, B. Pujala, A. K. Chakraborti and U. C. Banerjee, *Tetrahedron Lett.*, 2011, **52**, 5355–5358.

24 D. Zelaszczyk and K. Kiec, *Curr. Med. Chem.*, 2007, **14**, 53–65.

25 S. P. Panchgalle, R. G. Gore, S. P. Chavan and U. R. Kalkote, *Tetrahedron: Asymmetry*, 2009, **20**, 1767–1770.

26 J. Y. Zhang, H. M. Liu, H. W. Xu and L. H. Shan, *Tetrahedron: Asymmetry*, 2008, **19**, 512–517.

27 N. S. Thakur, J. Bhaumik, B. Sooram, L. Banoth and U. C. Banerjee, *ChemistrySelect*, 2016, **1**, 871–876.

28 B. P. Dwivedee, S. Ghosh, J. Bhaumik, L. Banoth and U. C. Banerjee, *RSC Adv.*, 2015, **5**, 15850–15860.

29 L. Banoth, N. S. Thakur, J. Bhaumik and U. C. Banerjee, *Chirality*, 2015, **27**, 382–391.

30 S. Hari Krishna and N. G. Karanth, *Catal. Rev.*, 2002, **44**, 161–4940.

31 A. Zaks and A. M. Klibanov, *J. Biol. Chem.*, 1988, **263**, 3194–3201.

32 A. M. Klibanov, *Nature*, 2001, **409**, 9–11.

33 M. Paravidino and U. Hanefeld, *Green Chem.*, 2011, **13**, 2651–2657.

34 J. E. Puskas, K. S. Seo and M. Y. Sen, *Eur. Polym. J.*, 2011, **47**, 524–534.

35 A. J. J. Straathof and J. A. Jongejan, *Enzyme Microb. Technol.*, 1997, **21**, 559–571.

36 J. Agustian, A. H. Kamaruddin and H. Y. Aboul-Enein, *Chirality*, 2017, 1–10.

37 E. Ł. Chojnacka, M. Staniszewska, M. Bondaryk, J. K. Maurin and M. Bretner, *Chirality*, 2016, **28**, 347–354.

38 M. D. Romero, L. Calvo, C. Alba and A. Daneshfar, *J. Biotechnol.*, 2007, **127**, 269–277.

39 L. E. Janes, R. J. Kazlauskas and S. S. West, *J. Org. Chem.*, 1997, **3**, 4560–4561.

40 V. Ferrario, C. Ebert, L. Knapic, D. Fattor, A. Basso, P. Spizzo and L. Gardossi, *Adv. Synth. Catal.*, 2011, **353**, 2466–2480.

41 http://www.uniprot.org/uniprot/P26504.

42 J. M. T. R. A. Laskowski, M. W. MacArthur and D. S. Moss, *J. Appl. Crystallogr.*, 1993, 283–291.

43 C. Colovos and T. O. Yeates, *Protein Sci.*, 1993, **2**, 1511–1519.

44 J. U. B. D. Eisenberg and R. Lothy, *Methods Enzymol.*, 1997, **277**, 396–404.

45 J. Bowie, R. Luthy and D. Eisenberg, *Science*, 1991, **253**, 164–170.

46 M. Wiederstein and M. J. Sippl, *Nucleic Acids Res.*, 2007, **35**, 407–410.

47 K. K. Kim, H. K. Song, D. H. Shin, K. Y. Hwang and S. W. Suh, *Structure*, 1997, **5**, 173–185.

48 C. Angkawidjaja, D. Ju You, H. Matsumura, K. Kuwahara, Y. Koga, K. Takano and S. Kanaya, *Fed. Eur. Biochem. Soc., Lett.*, 2007, **581**, 5060–5064.

49 A. Ghanem, *Tetrahedron*, 2007, **63**, 1721–1754.

50 D. Guieysse, J. Cortés, S. Puech-Guenot, S. Barbe, V. Lafaquière, P. Monsan, T. Siméon, I. André and M. Remaud-Siméon, *ChemBioChem*, 2008, **9**, 1308–1317.

51 C. Llc, S. S. Francisco and A. Guttman, *Chem. Genomics*, 2004, 59–60.

52 M. Höhne, S. Schätzle, H. Jochens, K. Robins and U. T. Bornscheuer, *Nat. Chem. Biol.*, 2010, **6**, 807–813.